MediciNova, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
MNOV Nasdaq 8731 http://www.medicinova.com 5.54 Stock Down -0.02

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MediciNova, Inc.

MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois - Jun 5th, 2017 2:00 pm
MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 69th Annual Meeting  in Boston - Apr 25th, 2017 5:00 pm
MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois - Apr 9th, 2017 5:00 pm
MNOV: MN-166 Making Progress in Numerous Indications… - Feb 27th, 2017 10:00 am
MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion - Dec 22nd, 2016 9:30 am
MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016 - Dec 15th, 2016 8:32 am
MNOV: Interim Analysis of MN-166 in Progressive MS in 4Q16; ODD granted to MN-166 for ALS - Oct 27th, 2016 9:00 am
MediciNova, Inc. :MNOV-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016 - Oct 11th, 2016 12:35 pm
MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16 - Jul 29th, 2016 10:00 am